Clinical Trial

Efficacy of Topical Tyrosine Versus Topical 5-Fluorouracil With Fractional Erbium YAG Laser

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
Vitiligo is an autoimmune disorder affecting the skin, specifically targeting pigment-producing melanocytes, leading to noticeable regions of depigmentation characterized by white spots. It is a widely prevalent skin disorder globally, affecting males and females almost equally, although it is reported slightly more frequently in females. In more than 60% of patients, the disease begins before the age of 30 and It has an estimated prevalence of roughly 0.2-2% across various populations, with around 0.4% in the European-derived white (EUR) population.
Trial Details
NCT Number NCT07742982
Lead Sponsor Aswan University
Conditions Focal Vitiligo
Enrollment 40 participants
Start Date 2026-06-01
Primary Completion 2027-06-01 (estimated)
Study Completion 2027-06-10 (estimated)
Updated on ClinicalTrials.gov 2026-08-11